The Individualized Accurate Diagnosis and Treatment of Chronic Objective Pulmonary Disease(COPD) Patients Based on Multidimensional Data

Recruiting

• Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Copd

• Registration Number: NCT04183530
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. Hence, the investigators' research integrated multi-dimensional data of COPD patients, which may provide an invaluable bioinformatic resource for understanding the underlying molecular alterations that drive disease progression, with the goal of developing individualized accurate diagnostic and therapeutic inventions.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) is an important event of disease progression worsening in airway function and respiratory symptoms, bringing about respiratory failure, and increasing the rates of mortality. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. In this context, the investigators are to perform comprehensive transcriptomic, proteomic, metabonomic and exosome characterization of COPD patients and healthy controls. Biological samples of COPD participants, including blood, urine, stool, saliva, bronchoalveolar lavage fluid and clinical characteristics are going to be collected from the remaining materials of the routine clinical examination. And samples of healthy controls will be collected from the rest of the healthy examination practice. By integrating the multi-dimensional data, the investigators aim to elucidate the impact of molecular alterations driving phenotypic variation and to delineate the mechanisms of AECOPD for prospective exploration of personalized, precision-based clinical care.

Study Timeline

• Study Start: 2019-10-16
• Study First Submitted: 2019-11-25
• Study First Submitted QC: 2019-11-27
• Study First Posted: 2019-12-03
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-15
• Last Update Posted: 2021-11-16
• Primary Completion: 2022-10-16
• Study Completion: 2024-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Patient has signed informed consent.
2. Patients diagnosed with COPD or fully healthy participants.

Exclusion Criteria

1. Tumor disease.
2. Heart disease.
3. Thyroid disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The metabolomics analysis of participates' urine or stool	through study completion, an average of 1 year	Predominately include metabolic target analysis, metabolic profiling analysis
The transcriptome analysis of participates' serum or plasma	through study completion, an average of 1 year	Include the transcriptome data of serum，plasma or exosomes inside
The proteomics analysis of bronchoalveolar lavage fluid and saliva	through study completion, an average of 1 year	Differentially expressed proteins between SCOPD and AECOPD which associated with disease progression were analyesd

Trial Locations

Locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China